

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:

NEW ASSIGNMENT

NATURE OF CONVEYANCE:

ASSIGNMENT

CONVEYING PARTY DATA

| Name             | Execution Date |
|------------------|----------------|
| Pfizer Health AB | 06/30/2004     |

RECEIVING PARTY DATA

|                 |             |
|-----------------|-------------|
| Name:           | Healon AB   |
| Street Address: | Rapsgatan 7 |
| City:           | Uppsala     |
| State/Country:  | SWEDEN      |
| Postal Code:    | SE-751 36   |

PROPERTY NUMBERS Total: 1

| Property Type  | Number  |
|----------------|---------|
| Patent Number: | 5576345 |

CORRESPONDENCE DATA

Fax Number: (714)247-8679  
*Correspondence will be sent via US Mail when the fax attempt is unsuccessful.*  
Phone: 714.247.8516  
Email: rebecca.smith@amo-inc.com  
Correspondent Name: Advanced Medical Optics, Inc.  
Address Line 1: 1700 E. St. Andrew Place  
Address Line 4: Santa Ana, CALIFORNIA 92705

NAME OF SUBMITTER:

Scott J. Catlin

Total Attachments: 10

source=Pfizer Health\_Healon#page1.tif  
source=Pfizer Health\_Healon#page2.tif  
source=Pfizer Health\_Healon#page3.tif  
source=Pfizer Health\_Healon#page4.tif  
source=Pfizer Health\_Healon#page5.tif  
source=Pfizer Health\_Healon#page6.tif  
source=Pfizer Health\_Healon#page7.tif

PATENT

REEL: 017073 FRAME: 0714

500074248

CH \$40.00 5576345

source=Pfizer Health\_Healon#page8.tif  
source=Pfizer Health\_Healon#page9.tif  
source=Pfizer Health\_Healon#page10.tif

# **Patent Assignment Agreement**

**between**

**PFIZER HEALTH AB**

**and**

**HEALON AB**

THIS PATENT ASSIGNMENT AGREEMENT is made and entered into on this \_\_\_\_ day of June 2004,

by and between

**PFIZER HEALTH AB**, a limited liability company duly established under the laws of Sweden, corporate identity number 556131-9608, having its registered office at Lindhagensgatan 100, 112 87 Stockholm, Sweden ("Seller"),

and

**HEALON AB**, a limited liability company duly established under the laws of Sweden, corporate identity number 556604-5422, having its registered office at 751 82 Uppsala, Sweden ("Buyer").

## 1. Introduction

1.1 On April 19, 2004, Seller and Buyer entered into an asset transfer agreement, as amended ("Asset Transfer Agreement"), under which Buyer agreed to purchase and acquire certain assets from Seller, including all of Seller's right, title and interest in and to the Patents (as defined below).

1.2 In view of the foregoing Seller and Buyer have agreed as follows.

## 2. Assignment

2.1 For the consideration set forth in the Asset Transfer Agreement the Seller hereby assigns to the Buyer the entire and exclusive right, title and interest of Seller in and to the patents and patent applications listed in Schedule A ("Patents").

2.2 The assignment of the rights in Section 2.1 is complete and includes all rights therein provided by international conventions and treaties and any and all rights of enforcement with respect to the Patents, including all rights to sue and recover for past infringements thereof, and any and all causes of action related thereto.

2.3 The Seller undertakes to execute and deliver, upon request and free of charge, any and all documents, forms and authorizations necessary for the registration of the assignment of the Patents with the relevant registration authorities (in all countries concerned).


- 2.4 The Seller shall pay all fees charged by the registration authorities in connection with the registration of the assignment of the Patents.

### 3. Miscellaneous


This Patent Assignment Agreement shall in all respects be deemed to be covered by Section 10.7 of the Asset Transfer Agreement on governing law and arbitration.

The parties hereto hereby cause this Patent Assignment Agreement to be duly executed by their respective authorized officers as of the day and year first above written.

PFIZER HEALTH AB



HEALON AB



Patents

If any patent or patent application included in the list below is owned by Pharmacia Groningen B.V. such patent shall be deemed to be excluded from this Schedule.

| No. | Registration/Application No.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Country                                                                                                                                                                                                                                                                                                          | Description                | Registered Owner                                     | Former ref. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------|------------------------------------------------------|-------------|
| 1.  | US 6558395<br>19104/01 <i>pending</i><br>EA 003591<br><br>00982028.3 <i>pending</i><br>P10016007-5 <i>pending</i><br>2392393 <i>pending</i><br>00816466.5 <i>pending</i><br>PV2002-1848 <i>pending</i><br>P200200269 <i>pending</i><br>03104949.1 <i>pending</i><br>P0203854 <i>pending</i><br>IN/PCT/2002/00981 <i>pending</i><br>W-00200201530 <i>pending</i><br>149571 <i>pending</i><br>2001-541437 <i>pending</i><br>2002-7006895 <i>pending</i><br>2002/005359 <i>pending</i><br>519003 <i>pending</i> | USA<br>Australia<br>Armenia, Azerbaijan, Belarus, Kazakhstan,<br>Kyrgyzstan, Moldova<br>Russian Federation, Tajikistan,<br>Turkmenistan<br>EP<br>Brazil<br>Canada<br>China<br>Czech Republic<br>Estonia<br>Hong Kong<br>Hungary<br>India<br>Indonesia<br>Israel<br>Japan<br>South Korea<br>Mexico<br>New Zealand | Intraocular lens implanter | Pharmacia &<br>Upjohn AB (today<br>Pfizer Health AB) | PHIA-00002  |

| No. | Registration/Application No.                                                                                                                                     | Country                                                                                                                                                                                                                               | Description                                                                                                     | Registered Owner                                 | Former ref. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|--------------------------------------------------|-------------|
|     | 20022568 <i>pending</i><br>P-355905 <i>pending</i><br>200203131-8 <i>pending</i><br>9904338-2 <i>pending</i><br>148879                                           | Norway<br>Poland<br>Singapore<br>Sweden<br>Taiwan                                                                                                                                                                                     |                                                                                                                 |                                                  |             |
| 2.  | US 4,764,360/2005<br>EP 0 202 257/2005<br><br>8405464-2<br>JP 1873877<br>CA 1256030/2006<br>MX 175155/2005                                                       | USA<br>Germany, Spain, France, UK, Italy,<br>Netherlands<br>Sweden<br>Japan<br>Canada<br>Mexico                                                                                                                                       | Compositions of HYA and a polymeric<br>colouring agent                                                          | Pharmacia AB<br>(today Pfizer<br>Health AB)      | PII-00562   |
| 3.  | US 5,681,825/2014                                                                                                                                                | USA                                                                                                                                                                                                                                   | High viscosity compositions of hyaluronic<br>acid                                                               | Kabi Pharmacia<br>AB (today Pfizer<br>Health AB) | PII-00933   |
| 4.  | US 6,537,795/2015<br>US 6,090,596<br>10/353891 <i>pending</i><br>EP 0 760 863<br><br>JP 500737/96 <i>pending</i><br>E221576<br>699404<br>CA 2191197<br>NZ 287583 | USA<br>USA<br>USA<br>Austria, Belgium, Switzerland, Germany,<br>Denmark, Spain, France, UK, Greece,<br>Ireland, Luxembourg, Monaco, Netherlands,<br>Portugal, Sweden, Italy<br>Japan<br>Austria<br>Australia<br>Canada<br>New Zealand | Production of high molecular weight<br>hyaluronic acid by super-encapsulated<br>mutants of group C streptococci | Pharmacia AB<br>(today Pfizer<br>Health AB)      | PII-01450   |

| No. | Registration/Application No.                                                                                                                                                     | Country                                                                                                                                                                                    | Description                                                                         | Registered Owner                           | Former ref. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|--------------------------------------------|-------------|
| 5.  | US 6,368,585/2017<br>US 6,086,597/2017<br>EP 1023077 pending<br>JP 3481952<br>2003-313532 <i>pending</i><br>AU 749522/2018<br>CA 2282757/2018<br>IL 131663 pending<br>01100778.7 | USA<br>USA<br>Designated countries<br>Japan<br>Japan<br>Australia<br>Canada<br>Israel<br>Hong Kong                                                                                         | Compositions of 18-40 mg/ml sodium HYA having a molecular weight of $1 \times 10^6$ | Pharmacia AB                               | PH-01742    |
| 6.  | US 5,135,540<br>EP 0 404 929<br><i>5025</i><br>E97795<br>JP 3083154<br>KR 162655<br>TW UM-66902 <i>Inactivated</i><br>635542                                                     | USA<br>Belgium, Austria, Switzerland, Germany, Denmark, Spain, France, Great Britain, Italy, Luxembourg, The Netherlands, Sweden<br>Austria<br>Japan<br>South Korea<br>Taiwan<br>Australia | IOL with one piece haptic extending radially from the body                          | Pharmacia AB<br>(today Pfizer Health AB)   | PH-00861    |
| 7.  | US 4,681,585<br>US 5,041,133<br>EP 0 161 764<br>JP 2069849                                                                                                                       | USA<br>USA<br>Germany, France, Great Britain, Italy, Sweden<br>Japan                                                                                                                       | IOL with non-PMMA haptics stable for radiation and heat                             | Kabi Pharmacia AB (today Pfizer Health AB) | PH-00862    |
| 8.  | US 467,789 <i>Inactivated</i><br>US 064,730 <i>Inactivated</i><br>EP 0 438 043                                                                                                   | US<br>US<br>Switzerland, Germany, France, Great Britain, The Netherlands, Sweden                                                                                                           | IOL with stretch strengthened haptics                                               | Pharmacia AB<br>(today Pfizer Health AB)   | PH-00865    |

PATENT

REEL: 017073 FRAME: 0721

| No. | Registration/Application No.                                                | Country                                                                                                                                                                                            | Description                                                                        | Registered Owner                                     | Former ref. |
|-----|-----------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|------------------------------------------------------|-------------|
| 9.  | US 5,429,838<br>EP 0 625 941<br>JP 3208428                                  | USA<br>Switzerland, Germany, Spain, France,<br>Great Britain, Italy, The Netherlands,<br>Sweden<br>Japan                                                                                           | IOL-Capping                                                                        | Pharmacia AB<br>(today Pfizer<br>Health AB)          | PHI-001306  |
| 10. | US 4,995,879                                                                | USA                                                                                                                                                                                                | IOL with haptics drawn polymeric material<br>with longitudinally oriented polymers | Kabi Pharmacia<br>AB (today Pfizer<br>Health AB)     | PHI-01324   |
| 11. | US 5,375,611<br>JP 516924/94 <i>pending</i>                                 | USA<br>Japan                                                                                                                                                                                       | IOL with chemical modification to prevent<br>from secondary cataract               | Pharmacia AB<br>(today Pfizer<br>Health AB)          | PHI-01329   |
| 12. | US 5,576,345<br>EP 0 696 917<br>JP 524162/94 <i>pending</i><br>CA 2,161,697 | USA<br>Denmark, Germany, Switzerland, Belgium,<br>Austria, Spain, France, Great Britain,<br>Greece, Ireland, Italy, Luxembourg,<br>Monaco, The Netherlands, Portugal,<br>Sweden<br>Japan<br>Canada | Use of taxol to prevent secondary cataract                                         | Pharmacia &<br>Upjohn AB (today<br>Pfizer Health AB) | PHI-01360   |
| 13. | US 5,376,115                                                                | USA                                                                                                                                                                                                | IOL with controlled vault following<br>implantation                                | Pharmacia AB<br>(today Pfizer<br>Health AB)          | PHI-01400   |
| 14. | US 5,549,669<br>JP 287245/94                                                | USA<br>Japan                                                                                                                                                                                       | IOL with non-symmetric haptic crosssection                                         | Pharmacia AB<br>(today Pfizer<br>Health AB)          | PHI-01518   |

| No. | Registration/Application No.                                                                                                                                            | Country                                  | Description                                               | Registered Owner                               | Former ref. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------|-----------------------------------------------------------|------------------------------------------------|-------------|
| 15. | JP 533247/96 <i>pending</i><br>EP 96914498.9 <i>pending</i>                                                                                                             | Japan<br>EPO                             | HA-anthracyclin complex for preventing secondary cataract | Pharmacia & Upjohn AB (today Pfizer Health AB) | PII-01558   |
| 16. | US 6,011,082<br>US 6,251,965<br>US 09/876,572 <i>pending</i><br>US <i>pending</i> - appl. number missing<br>EP 98924983.4 <i>pending</i><br>JP 502596/99 <i>pending</i> | USA<br>USA<br>USA<br>USA<br>EPO<br>Japan | Silicon IOL with heparinized surface                      | Pharmacia AB (today Pfizer Health AB)          | PII-01740   |

| No. | Registration/Application No.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Country                                                                                                                                                                                                                                                                                                                                                                                                          | Description                                | Registered Owner                            | Former ref. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------|---------------------------------------------|-------------|
| 17. | US 6,030,416<br>CA 2,317,746 <i>pending</i><br>BR P19907757-4 <i>pending</i><br>AU 748650<br>JP 2000-531135 <i>pending</i><br>HU P0100231 <i>pending</i><br>KR 2000-7008881 <i>pending</i><br>CN 99802935.1 <i>pending</i><br>CZ PV2000-2905 <i>pending</i><br>MX 00077905 <i>pending</i><br>NO 2000 4050 <i>pending</i><br>NZ 505585<br>PL P342842 <i>pending</i><br>RU 2000123549/14 <i>pending</i><br>SG 74865<br>SK PV1128-2000 <i>pending</i><br>TR 2000/02259 <i>pending</i><br>IL 137807 <i>pending</i><br>HK 01109215.9 <i>pending</i><br>EP 1 056 415 | USA<br>Canada<br>Brazil<br>Australia<br>Japan<br>Hungary<br>South Korea<br>China<br>Czech Republic<br>Mexico<br>Norway<br>New Zealand<br>Poland<br>Russia<br>Singapore<br>Slovakia<br>Turkey<br>Israel<br>Hong Kong<br>Portugal, Luxembourg, Italy, Ireland,<br>Greece, Great Britain, Cyprus, Denmark,<br>Spain, Finland, Austria, Belgium, France,<br>Switzerland, Germany, Monaco, The<br>Netherlands, Sweden | IOLs made stretch crystallisable silicones | Pharmacia AB<br>(today Pfizer<br>Health AB) | PH-01810    |

96/12/9

| No. | Registration/Application No.                                                                                                                                                                                                                                                                                                          | Country                                                                                                                                                                                                                                                                                                                          | Description                                  | Registered Owner                            | Former ref. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------|---------------------------------------------|-------------|
| 18. | US 6,036,891<br>EP 1 077 952<br><i>51959</i><br>JP 2000-548311 <i>pending</i><br>ZA 2000/7285<br>NZ 507496 <i>pending</i><br>MX 0011063 <i>pending</i><br>KR 2000-7012524 <i>pending</i><br>HK 01108897.6 <i>pending</i><br>CN 99806023.2 <i>pending</i><br>CA 2,328,912 <i>pending</i><br>BR PI9910358-3 <i>pending</i><br>AU 754155 | USA<br>Finland, Austria, Belgium, Cyprus,<br>Denmark, France, UK, Germany, Greece,<br>Ireland, Italy, Liechtenstein, Luxembourg,<br>Monaco, Netherlands, Portugal, Spain,<br>Sweden, Switzerland, Turkey<br>Japan<br>South Africa<br>New Zealand<br>Mexico<br>South Korea<br>Hong Kong<br>China<br>Canada<br>Brazil<br>Australia | IOIs from copolymerised UV blockers          | Pharmacia AB<br>(today Pfizer<br>Health AB) | PII-01821   |
| 19. | US 6,066,172<br>US 6,361,561<br>US 10/013,692 <i>pending</i>                                                                                                                                                                                                                                                                          | USA<br>USA<br>USA                                                                                                                                                                                                                                                                                                                | Injectable IOIs from thermocurable silicones | Pharmacia AB<br>(today Pfizer<br>Health AB) | PII-01831   |
| 20. | US 6,399,734<br>US 10/134,710 <i>pending</i>                                                                                                                                                                                                                                                                                          | USA<br>USA                                                                                                                                                                                                                                                                                                                       | Injectable IOIs from photocurable silicones  | Pharmacia AB<br>(today Pfizer<br>Health AB) | PII-01839   |

PATENT

RECORDED: 01/27/2006

REEL: 017073 FRAME: 0725